drugset / Trial / NCT05839106
Phase I/IIa Study for PM1032 in the Treatment of Patients With Advanced Solid Tumors
NaSequentialOpen-labelTreatment
Summary
The study is being conducted to evaluate safety, tolerability, pharmacokinetics and preliminary efficacy of PM1032 for patients with advanced tumors, also to explore the recommended Phase Ⅱ Dose（RP2D） of PM1032.
Timeline
- Start
- 2022-07-08
- Primary completion
- 2025-04-10
- Completion
- 2025-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PM1032 | Unknown | 0.3 mg/kg | Intravenous |
| Subject | PM1032 | Unknown | 12 mg/kg | Intravenous |
Indications
No indication recorded.